Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 4.81
SURG's Cash to Debt is ranked higher than
57% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. SURG: 4.81 )
Ranked among companies with meaningful Cash to Debt only.
SURG' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 10000.00 Max: No Debt
Current: 4.81
Equity to Asset 0.72
SURG's Equity to Asset is ranked higher than
66% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. SURG: 0.72 )
Ranked among companies with meaningful Equity to Asset only.
SURG' s Equity to Asset Range Over the Past 10 Years
Min: 0.57  Med: 0.76 Max: 0.98
Current: 0.72
0.57
0.98
Interest Coverage 74.27
SURG's Interest Coverage is ranked higher than
58% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 38.74 vs. SURG: 74.27 )
Ranked among companies with meaningful Interest Coverage only.
SURG' s Interest Coverage Range Over the Past 10 Years
Min: 1.56  Med: 26.82 Max: 241.11
Current: 74.27
1.56
241.11
F-Score: 5
Z-Score: 5.83
M-Score: -2.80
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 8.12
SURG's Operating margin (%) is ranked higher than
66% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 2.65 vs. SURG: 8.12 )
Ranked among companies with meaningful Operating margin (%) only.
SURG' s Operating margin (%) Range Over the Past 10 Years
Min: 3.3  Med: 9.26 Max: 15
Current: 8.12
3.3
15
Net-margin (%) 5.97
SURG's Net-margin (%) is ranked higher than
64% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. SURG: 5.97 )
Ranked among companies with meaningful Net-margin (%) only.
SURG' s Net-margin (%) Range Over the Past 10 Years
Min: 1.84  Med: 5.65 Max: 11.01
Current: 5.97
1.84
11.01
ROE (%) 6.81
SURG's ROE (%) is ranked higher than
63% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. SURG: 6.81 )
Ranked among companies with meaningful ROE (%) only.
SURG' s ROE (%) Range Over the Past 10 Years
Min: 2.57  Med: 7.19 Max: 16.86
Current: 6.81
2.57
16.86
ROA (%) 4.95
SURG's ROA (%) is ranked higher than
67% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: -0.01 vs. SURG: 4.95 )
Ranked among companies with meaningful ROA (%) only.
SURG' s ROA (%) Range Over the Past 10 Years
Min: 1.54  Med: 4.76 Max: 11.03
Current: 4.95
1.54
11.03
ROC (Joel Greenblatt) (%) 17.92
SURG's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 4.86 vs. SURG: 17.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SURG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 5.99  Med: 18.75 Max: 37.75
Current: 17.92
5.99
37.75
Revenue Growth (3Y)(%) 7.50
SURG's Revenue Growth (3Y)(%) is ranked higher than
65% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. SURG: 7.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SURG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.6  Med: 5.10 Max: 50.8
Current: 7.5
-2.6
50.8
EBITDA Growth (3Y)(%) -4.50
SURG's EBITDA Growth (3Y)(%) is ranked lower than
63% of the 194 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. SURG: -4.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SURG' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -56.3  Med: 17.65 Max: 203.7
Current: -4.5
-56.3
203.7
EPS Growth (3Y)(%) -9.10
SURG's EPS Growth (3Y)(%) is ranked lower than
67% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. SURG: -9.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SURG' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -37  Med: 0.00 Max: 122.4
Current: -9.1
-37
122.4
» SURG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2015

SURG Guru Trades in Q1 2015

Jim Simons 387,560 sh (+83.16%)
Chuck Royce 969,274 sh (-16.93%)
» More
Q2 2015

SURG Guru Trades in Q2 2015

Jim Simons 480,436 sh (+23.96%)
Chuck Royce 895,674 sh (-7.59%)
» More
Q3 2015

SURG Guru Trades in Q3 2015

Mario Gabelli 12,000 sh (New)
Jim Simons 438,800 sh (-8.67%)
Chuck Royce 671,774 sh (-25.00%)
» More
Q4 2015

SURG Guru Trades in Q4 2015

Jim Simons Sold Out
Chuck Royce Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SURG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NAS:IRIX, OTCPK:XVIPF, NAS:FONR, NAS:EYES, OTCPK:VRAY, AMEX:CVRS, NAS:AXGN, OTCPK:SOMNF, NAS:CUTR, NAS:ACRX, NYSE:GI, OTCPK:VICA, OTCPK:MHMNF, NAS:IRMD, NAS:RTIX, NAS:DRAD, NAS:SPNE, NAS:TNDM, OTCPK:AONCF, NAS:ELOS » details


Synergetics USA Inc is a Delaware corporation incorporated on June 2, 2005 in connection with the reverse merger of Synergetics, Inc. and Valley Forge Scientific Corp. The Company is a supplier of precision surgical devices. It develops, manufactures, and markets disposable and durable equipment for use in ophthalmologic, neurosurgical, and other microsurgical applications. The Company's product lines focus upon precision engineered, disposable and reusable devices, procedural kits and the delivery of various energy modalities for the performance of surgery, including: laser energy, ultrasonic energy, radio frequency energy for electrosurgery and lesion generation and visible light energy for illumination, and where applicable, simultaneous infusion (irrigation) of fluids into the operative field. It's ophthalmic and vitreoretinal surgical devices and equipment compete against manufacturers of similar products, including those sold by its major competitors, Alcon, Bausch & Lomb, Inc., Dutch Ophthalmic Research Center and Iridex. The Company is subject to macro-economic fluctuations in the United States, the countries of Europe and the economies of other countries throughout the world. Medical device companies are subject to rigorous regulation, including by the FDA and numerous other federal, state and foreign governmental authorities.

Ratios

vs
industry
vs
history
P/E(ttm) 37.17
SURG's P/E(ttm) is ranked lower than
66% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 28.34 vs. SURG: 37.17 )
Ranked among companies with meaningful P/E(ttm) only.
SURG' s P/E(ttm) Range Over the Past 10 Years
Min: 5.03  Med: 26.23 Max: 88
Current: 37.17
5.03
88
Forward P/E 18.69
SURG's Forward P/E is ranked higher than
82% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 24.63 vs. SURG: 18.69 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 37.17
SURG's PE(NRI) is ranked lower than
65% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: 28.88 vs. SURG: 37.17 )
Ranked among companies with meaningful PE(NRI) only.
SURG' s PE(NRI) Range Over the Past 10 Years
Min: 5  Med: 25.46 Max: 85
Current: 37.17
5
85
Price/Owner Earnings (ttm) 22.45
SURG's Price/Owner Earnings (ttm) is ranked higher than
67% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 32.52 vs. SURG: 22.45 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
SURG' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 1.61  Med: 19.81 Max: 305.38
Current: 22.45
1.61
305.38
P/B 2.50
SURG's P/B is ranked higher than
56% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 2.95 vs. SURG: 2.50 )
Ranked among companies with meaningful P/B only.
SURG' s P/B Range Over the Past 10 Years
Min: 0.49  Med: 1.88 Max: 6.46
Current: 2.5
0.49
6.46
P/S 2.27
SURG's P/S is ranked higher than
61% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 3.51 vs. SURG: 2.27 )
Ranked among companies with meaningful P/S only.
SURG' s P/S Range Over the Past 10 Years
Min: 0.34  Med: 1.69 Max: 5.29
Current: 2.27
0.34
5.29
PFCF 20.58
SURG's PFCF is ranked higher than
67% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 31.08 vs. SURG: 20.58 )
Ranked among companies with meaningful PFCF only.
SURG' s PFCF Range Over the Past 10 Years
Min: 1.6  Med: 16.17 Max: 131.33
Current: 20.58
1.6
131.33
POCF 17.47
SURG's POCF is ranked higher than
58% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 20.58 vs. SURG: 17.47 )
Ranked among companies with meaningful POCF only.
SURG' s POCF Range Over the Past 10 Years
Min: 1.55  Med: 17.10 Max: 194.21
Current: 17.47
1.55
194.21
EV-to-EBIT 26.56
SURG's EV-to-EBIT is ranked lower than
58% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 22.17 vs. SURG: 26.56 )
Ranked among companies with meaningful EV-to-EBIT only.
SURG' s EV-to-EBIT Range Over the Past 10 Years
Min: -933.5  Med: 16.00 Max: 151.3
Current: 26.56
-933.5
151.3
EV-to-EBITDA 18.09
SURG's EV-to-EBITDA is ranked higher than
50% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 18.09 vs. SURG: 18.09 )
Ranked among companies with meaningful EV-to-EBITDA only.
SURG' s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.9  Med: 12.20 Max: 287.9
Current: 18.09
2.9
287.9
Shiller P/E 39.82
SURG's Shiller P/E is ranked higher than
53% of the 45 Companies
in the Global Medical Devices industry.

( Industry Median: 41.87 vs. SURG: 39.82 )
Ranked among companies with meaningful Shiller P/E only.
SURG' s Shiller P/E Range Over the Past 10 Years
Min: 12.5  Med: 31.00 Max: 281.67
Current: 39.82
12.5
281.67
Current Ratio 4.78
SURG's Current Ratio is ranked higher than
76% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.83 vs. SURG: 4.78 )
Ranked among companies with meaningful Current Ratio only.
SURG' s Current Ratio Range Over the Past 10 Years
Min: 1.76  Med: 6.88 Max: 17.49
Current: 4.78
1.76
17.49
Quick Ratio 3.05
SURG's Quick Ratio is ranked higher than
68% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. SURG: 3.05 )
Ranked among companies with meaningful Quick Ratio only.
SURG' s Quick Ratio Range Over the Past 10 Years
Min: 0.71  Med: 4.73 Max: 13.9
Current: 3.05
0.71
13.9
Days Inventory 168.69
SURG's Days Inventory is ranked lower than
65% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 134.88 vs. SURG: 168.69 )
Ranked among companies with meaningful Days Inventory only.
SURG' s Days Inventory Range Over the Past 10 Years
Min: 166.91  Med: 197.57 Max: 264.84
Current: 168.69
166.91
264.84
Days Sales Outstanding 67.80
SURG's Days Sales Outstanding is ranked higher than
53% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 68.74 vs. SURG: 67.80 )
Ranked among companies with meaningful Days Sales Outstanding only.
SURG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 62.65  Med: 66.73 Max: 83.84
Current: 67.8
62.65
83.84
Days Payable 42.77
SURG's Days Payable is ranked lower than
68% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 62.25 vs. SURG: 42.77 )
Ranked among companies with meaningful Days Payable only.
SURG' s Days Payable Range Over the Past 10 Years
Min: 25  Med: 35.60 Max: 53.82
Current: 42.77
25
53.82

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 8.92
SURG's Price/Net Current Asset Value is ranked lower than
60% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: 7.14 vs. SURG: 8.92 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SURG' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.81  Med: 6.38 Max: 41.09
Current: 8.92
2.81
41.09
Price/Tangible Book 5.77
SURG's Price/Tangible Book is ranked lower than
62% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 4.19 vs. SURG: 5.77 )
Ranked among companies with meaningful Price/Tangible Book only.
SURG' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.07  Med: 4.15 Max: 12.35
Current: 5.77
2.07
12.35
Price/Projected FCF 1.40
SURG's Price/Projected FCF is ranked higher than
72% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. SURG: 1.40 )
Ranked among companies with meaningful Price/Projected FCF only.
SURG' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.73  Med: 2.35 Max: 11.68
Current: 1.4
0.73
11.68
Price/Median PS Value 1.35
SURG's Price/Median PS Value is ranked lower than
68% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. SURG: 1.35 )
Ranked among companies with meaningful Price/Median PS Value only.
SURG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.33  Med: 1.43 Max: 3.77
Current: 1.35
0.33
3.77
Price/Graham Number 3.08
SURG's Price/Graham Number is ranked lower than
62% of the 147 Companies
in the Global Medical Devices industry.

( Industry Median: 2.28 vs. SURG: 3.08 )
Ranked among companies with meaningful Price/Graham Number only.
SURG' s Price/Graham Number Range Over the Past 10 Years
Min: 1.28  Med: 2.40 Max: 8.23
Current: 3.08
1.28
8.23
Earnings Yield (Greenblatt) (%) 3.80
SURG's Earnings Yield (Greenblatt) (%) is ranked higher than
72% of the 341 Companies
in the Global Medical Devices industry.

( Industry Median: -0.40 vs. SURG: 3.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SURG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.7  Med: 6.20 Max: 27
Current: 3.8
0.7
27
Forward Rate of Return (Yacktman) (%) -8.37
SURG's Forward Rate of Return (Yacktman) (%) is ranked lower than
84% of the 117 Companies
in the Global Medical Devices industry.

( Industry Median: 7.42 vs. SURG: -8.37 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SURG' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -9.6  Med: -0.40 Max: 1024
Current: -8.37
-9.6
1024

More Statistics

Revenue (TTM) (Mil) $75.02
EPS (TTM) $ 0.18
Short Percentage of Float0.26%
52-Week Range $3.18 - 6.74
Shares Outstanding (Mil)25.63

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Jul16
Revenue (Mil $)
EPS ($) 0.23
EPS w/o NRI ($) 0.23
EPS Growth Rate
(3Y to 5Y Estimate)
15.00%
Dividends Per Share ($)
» More Articles for SURG

Headlines

Articles On GuruFocus.com
Synergetics USA: A Growth Story Amidst an Aging Population Aug 30 2012 
Synergetics Up 30% after Approval for Eye Surgery Device Jun 28 2012 
Synergetics USA Inc. (SURG) EVP & COO Kurt W Jr Gampp sells 43,000 Shares Mar 15 2011 
Weekly CFO Buys Highlight: CNLG, SIFID, FUL, SURG, TYL Jan 15 2011 
Synergetics USA Inc. (SURG) President and CEO David M Hable sells 17,000 Shares Jan 07 2011 
Weekly CFO Buys Highlight: COIN, INTC, SURG, IBCA, AUMN Oct 24 2010 

More From Other Websites
One Reason Why Valeant (VRX) Stock Is Retreating Today Feb 11 2016
Stryker (SYK) Set to Acquire Synergetics' Neuro Portfolio Feb 11 2016
Do Hedge Funds Love Points International Ltd (USA) (PCOM)? Nov 30 2015
Hedge Funds Aren’t Crazy About CDI Corp. (CDI) Anymore Nov 24 2015
SYNERGETICS USA INC Financials Oct 17 2015
SYNERGETICS USA INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion... Oct 15 2015
Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Synergetics USA, Inc. Oct 15 2015
Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Synergetics USA, Inc. Oct 15 2015
Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Synergetics USA, Inc. Oct 15 2015
SYNERGETICS USA INC Files SEC form 10-K, Annual Report Oct 14 2015
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced... Oct 05 2015
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced... Oct 05 2015
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced... Oct 05 2015
SYNERGETICS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Synergetics USA,... Sep 17 2015
WeissLaw LLP Investigates the Synergetics USA Inc. Acquisition Sep 09 2015
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Synergetics... Sep 08 2015
SYNERGETICS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Synergetics USA,... Sep 08 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Synergetics USA, Inc. of... Sep 08 2015
5 Top Biotech Stocks That Ran This Past Week Sep 05 2015
SYNERGETICS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Synergetics USA,... Sep 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)